1. ALLA AKTIER
  2. NYHETER
  3. BIOVICA INTERNATIONAL

Biovica International

Nyheter Biovica International Nyheter alla bolag
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

Biovica signs second agreement with leading US healthcare provider

MARKN.

Biovica, active in cancer monitoring, today announces that the company has signed its second US hospital agreement for DiviTum® TKa with the largest healthcare provider in Missouri, a state covering about two percent of the US population.

The healthcare provider operates 18 hospitals of which one is a National Cancer Institute (NCI) Comprehensive Cancer Center and has been a partner to Biovica during the clinical development of DiviTum® TKa.

“We are immensely grateful for having had such an outstanding partner throughout our clinical development process and look forward to further deepening our partnership. The agreement represents the growing interest in and tremendous potential impact of DiviTum® TKa in the US market,” said Warren Cresswell, President of the Americas.

Contact

Anders Rylander, CEO
Phone: +46 76 666 16 47
E-mail: anders.rylander@biovica.com

Anders Morén, CFO
Phone: +46 73 125 92 46
E-mail: anders.moren@biovica.com

Biovica – Treatment decisions with greater confidence

Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica’s assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: “Improved care for cancer patients.” Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: www.biovica.com

Attachments

Biovica signs second agreement with leading US healthcare provider

Datum 2023-09-25, kl 08:00
Källa MFN
Bifogade filer
Biovica signs second agreement with leading US healthcare provider